Breaking Finance News

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) target price raised to $22.00, issued a report today by HC Wainwright

Yesterday Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) traded 2.95% higher at $13.22. The company’s 50-day moving average is $11.11 and its 200-day moving average is $9.14. The last closing price is up 48.88% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 837,096 shares of the stock were exchanged, up from an average trading volume of 230,128

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) had its target price raised to $22.00 by HC Wainwright in a report released 10/7/2016. The new target price indicates a possible upside of 0.66% based on the company's last closing price.

See Chart Below

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)

Zynerba Pharmaceuticals Inc has a 52 week low of $4.64 and a 52 week high of $21.56 The company’s market cap is currently $0.

General Information About Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome. The Company's ZYN002 is synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear that is designed to provide controlled drug delivery with once- or twice-daily dosing. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The Company intends to test the ZYN001 patch for application to the arm, back and thigh. The Company intends to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.